Investigating a genetic variant's role in higher H. pylori infections among African Americans
Role of African-centric TP53 variant in higher H. pylori prevalence in African Americans
This study is looking at how a certain gene variation, mostly found in people of African descent, might make African Americans more likely to get H. pylori infections, and it aims to understand how this gene affects the immune system's ability to fight off the infection so that better treatments can be developed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11001494 on NIH RePORTER |
What this research studies
This research explores how a specific genetic variant of the TP53 gene, found predominantly in individuals of African descent, contributes to the higher prevalence of H. pylori infections in African Americans. The study focuses on understanding how this variant affects immune responses, particularly in macrophages, which are crucial for fighting infections. By analyzing samples from African American individuals with H. pylori, the researchers aim to uncover the mechanisms behind the increased infection rates and develop potential therapeutic strategies to enhance immune response and clear the infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American individuals who are seropositive for H. pylori.
Not a fit: Patients who do not have H. pylori infections or are not of African descent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for H. pylori infections in African Americans, potentially reducing the risk of related gastric diseases.
How similar studies have performed: While the specific genetic variant's role in H. pylori prevalence is novel, similar studies have shown that genetic factors can significantly influence infection rates and immune responses.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Claiborne, Daniel Thomas — Wistar Institute
- Study coordinator: Claiborne, Daniel Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.